Cojutti Pier Giorgio, Ramos-Martin Virginia, Schiavon Isabella, Rossi Paolo, Baraldo Massimo, Hope William, Pea Federico
Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, Udine, Italy.
Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02134-16. Print 2017 Mar.
A retrospective study was conducted in a large sample of acutely hospitalized older patients who underwent therapeutic drug monitoring during levofloxacin treatment. The aim was to assess the population pharmacokinetics (popPK) and pharmacodynamics of levofloxacin among older patients. PopPK and Monte Carlo simulation were performed to define the permissible doses in older patients according to various degrees of renal function. Classification and regression tree (CART) analysis was used to detect the cutoff 24-hour area under the concentration-time curve (AUC)/MIC ratio that best correlated with the clinical outcome. The probability of target attainment (PTA) of this value was calculated against different pathogens. A total of 168 patients were included, and 330 trough and 239 peak concentrations were used for the popPK analysis. Creatinine clearance (CrCL) was the only covariate that improved the model fit (levofloxacin CL = 0.399 + 0.051 × CrCL [creatinine clearance estimated by means of the chronic kidney disease epidemiology]). Drug doses ranged between 500 mg every 48 h and 500 mg every 12 h in relation to different renal functions. The identified cutoff AUC/MIC ratio (≥95.7) was the only covariate that correlated with a favorable clinical outcome in multivariate regression analysis (odds ratio [OR], 20.85; 95% confidence interval [CI], 1.56 to 186.73). PTAs were optimal (>80%) against and , borderline against , and suboptimal against The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of ≤0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk. Conversely, the addition of another active antimicrobial should be considered whenever treating infections caused by less susceptible pathogens.
对一大群急性住院的老年患者进行了一项回顾性研究,这些患者在左氧氟沙星治疗期间接受了治疗药物监测。目的是评估老年患者中左氧氟沙星的群体药代动力学(popPK)和药效学。进行了群体药代动力学和蒙特卡洛模拟,以根据不同程度的肾功能确定老年患者的允许剂量。使用分类与回归树(CART)分析来检测与临床结果最相关的24小时浓度-时间曲线下面积(AUC)/最低抑菌浓度(MIC)比值的临界值。针对不同病原体计算该值的目标达成概率(PTA)。共纳入168例患者,330个谷浓度和239个峰浓度用于群体药代动力学分析。肌酐清除率(CrCL)是唯一能改善模型拟合度的协变量(左氧氟沙星清除率CL = 0.399 + 0.051×CrCL [采用慢性肾脏病流行病学方法估算的肌酐清除率])。根据不同的肾功能,药物剂量范围为每48小时500毫克至每12小时500毫克。在多变量回归分析中,确定的临界AUC/MIC比值(≥95.7)是唯一与良好临床结果相关的协变量(优势比[OR],20.85;95%置信区间[CI],1.56至186.73)。针对肺炎链球菌和金黄色葡萄球菌的PTA最佳(>80%),针对肺炎克雷伯菌的PTA处于临界值,针对铜绿假单胞菌的PTA欠佳。我们研究中确定的左氧氟沙星剂量可能对治疗由细菌病原体引起的感染有效,对于不同程度肾功能的老年患者,当MIC≤0.5毫克/升时,同时将毒性风险降至最低。相反,在治疗由较不敏感病原体引起的感染时,应考虑加用另一种活性抗菌药物。